Stockreport

VYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]

VYNE Therapeutics Inc.  (VYNE) 
PDF US$2.71 loss per share (improved from US$10.65 loss in FY 2022). All figures shown in the chart above are for the trailing 12 month (TTM) period VYNE Therapeutics E [Read more]